Understanding why some childhood ependymomas resist radiation treatment
Ependymomics: Multiomic Approach to Radioresistance of Ependymomas in Children and Adolescents
This study looks at why some childhood brain tumors called ependymomas don’t respond well to radiation treatment to help find better ways to treat them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 370 (estimated) |
| Ages | N/A to 25 Years |
| Sex | All |
| Sponsor | Institut Claudius Regaud Academic / other |
| Drugs / interventions | radiation, chemotherapy |
| Locations | 1 site (Toulouse) |
| Trial ID | NCT05151718 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on childhood ependymomas, the second most common pediatric brain tumor, which often relapses after treatment. It employs a multi-omics approach, integrating clinical, imaging, and molecular data to identify predictive characteristics of relapse and innovative radiotherapy targets. By analyzing a large cohort of patients treated in France, the study aims to correlate imaging biomarkers with genomic markers to better understand radioresistance in ependymomas. The ultimate goal is to enhance treatment strategies and improve patient outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are children diagnosed with intracranial ependymoma who have been treated and are part of the PEPPI study or the SIOP II Ependymoma program.
Not a fit: Patients with ependymomas who have not been treated or are not part of the specified programs may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more effective treatment strategies for children with ependymomas, potentially reducing relapse rates.
How similar studies have performed: Previous studies have shown promising results in understanding ependymoma treatment resistance, but this multi-omics approach is relatively novel and aims to build on existing findings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * children with intracranial ependymoma * treated * included in PEPPI study, pediaRT or in SIOP II Ependymoma french program Exclusion Criteria: * NA
Where this trial is running
Toulouse
- Institut Claudius Regaud — Toulouse, France (Recruiting)
Study contacts
- Study coordinator: Anne LAPRIE, PU-PH
- Email: laprie.anne@iuct-oncopole.fr
- Phone: + 33 (0)5 31 15 50 50
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.